SUZHOU, China, Jan. 15, 2022– CStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company, today announced that the registrational clinical data from sugemalimab (the GEMSTONE-301 study) in stage III non-small cell lung cancer (NSCLC) were published in the world-leading clinical oncology journal, The Lancet Oncology.  Sugemalimab as a consolidation therapy demonstrated